Clinical experience with intravenous iron

Clinical update: intravenous iron for anaemia.

For nearly half a century, parenteral iron has been considered dangerous and for use only in extreme situations and when oral iron was not tolerated. This proscription was based largely on poorly characterised and infrequent anaphylactoid reactions to the high-molecular-weight dextran preparation (Imferon) that for most of this time was the only product available. Moreover, when parenteral iron...

Intravenous Iron Therapy with Saccharated Iron Oxide

Treatment of glioblastoma with intravenous taurolidine. First clinical experience.

BACKGROUND Despite progress in diagnosis and therapy, the prognosis of patients with glioblastoma remains poor. Recently it has been found that the antibacterial agent taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of programmed cell death. This paper reports on intravenous taurolidine treatment in two patients with a progressive glioblastoma ...

Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Erythropoiesis may be limited by absolute or functional iron deficiency or when chronic inflammatory conditions lead to iron sequestration. Intravenous iron may be indicated when oral iron cannot address the deficiency. Ferric carboxymaltose (FCM) is a nondextran iron preparation recently approved in the United States for intravenous treatment of iron deficiency anemia (IDA) in adult patients w...

The Treatment of Iron-deficiency Anemia with Intravenous Iron Dextran.

I N THE THERAPY of iron-deficiency anemia, iron given orally is safe, effective, inexpensive, and is usually the treatment of choice, but occasionally when a rapid replenishment of iron stores is desired, administration by the parenteral route is indicated. Heath, Strauss and Castle,1 in 1938, showed that when 16-32 mg. of iron as ferric ammonium citrate is injected subcutaneously or intramuscu...